We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+4.57%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.71B
AUM Growth
-$696M
Cap. Flow
-$760M
Cap. Flow %
-13.31%
Top 10 Hldgs %
73.58%
Holding
34
New
1
Increased
10
Reduced
17
Closed
4

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$159M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$56.2M
3
QURE icon
uniQure
QURE
+$19.5M
4
VERA icon
Vera Therapeutics
VERA
+$13.4M
5
ALKS icon
Alkermes
ALKS
+$13.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$361M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$171M
3
UTHR icon
United Therapeutics
UTHR
+$91.2M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$82.5M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$43.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
26
MannKind Corp
MNKD
$1.24B
$21.9M 0.38%
5,850,000
-2,900,000
-33% -$12.8M
GLUE icon
27
Monte Rosa Therapeutics
GLUE
$1.33B
$16.8M 0.29%
3,725,000
-920,548
-20% -$4.11M
SEPN
28
Septerna Inc
SEPN
$1.78B
$13.1M 0.23%
1,237,500
-100,000
-7% -$824K
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$2.54B
$12M 0.21%
330,000
-500,000
-60% -$18M
WHWK
30
Whitehawk Therapeutics
WHWK
$232M
$5.33M 0.09%
2,849,402
– –
AUTL
31
Autolus Therapeutics
AUTL
$532M
– –
-9,910,642
Closed -$15.4M
PCVX icon
32
Vaxcyte
PCVX
$8.5B
– –
-1,000,000
Closed -$37.8M
SRPT icon
33
Sarepta Therapeutics
SRPT
$1.77B
– –
-2,674,835
Closed -$171M
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-625,000
Closed -$82.5M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Avoro Capital Advisors held 34 positions worth $5.71B, down 11% from $6.41B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors withdrew a net $760M in Q2 2025, closing 4 positions and reducing 17 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $171M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Akero Therapeutics worth $187M.

  • Avoro Capital Advisors's largest Q2 2025 buy was Akero Therapeutics: 3,500,000 shares worth $187M.
  • Avoro Capital Advisors added most to MoonLake Immunotherapeutics in Q2 2025, an estimated $56.2M increase.
  • Avoro Capital Advisors's biggest Q2 2025 reduction was Blueprint Medicines, cutting an estimated $361M.
  • Avoro Capital Advisors fully exited Sarepta Therapeutics in Q2 2025, selling an estimated $171M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $5.71B portfolio in Q2 2025.
  • Avoro Capital Advisors opened 1 new position and closed 4 in Q2 2025.
  • Avoro Capital Advisors's portfolio value fell 11% quarter-over-quarter to $5.71B.

Based on Avoro Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.